24 August 2021
EMA/472810/2021
Veterinary Medicines Division

Committee for Medicinal Products for Veterinary Use

CVMP assessment report for Ingelvac CircoFLEX (EMEA/V/C/WS1921)

Vaccine common name: Porcine circovirus vaccine (inactivated)

Assessment report as adopted by the CVMP with all information of a commercially confidential nature deleted.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged.

Table of contents

1. Introduction

1.1. Submission of the variation application

In accordance with Article 20 of Commission Regulation (EC) No 1234/2008, the marketing authorisation holder, Boehringer Ingelheim Vetmedica GmbH (the applicant), submitted to the European Medicines Agency (the Agency) on 18 December 2020 an application for a type II variation for Ingelvac CircoFLEX and another related nationally authorised product Ingelvac PRRSFLEX EU, following a worksharing procedure.

1.2. Scope of the variation

Variation(s) requested		Type
C.I.4	Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	II

The worksharing variation is to change the product information to add the associated mixed use of Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU (a live modified vaccine registered via decentralised procedure). Additionally, the MAH is proposing some editorial changes to Part 2 of the Dossier and minor QRD updates to the product information.

1.3. Changes to the dossier held by the European Medicines Agency

This application relates to the following sections of the current dossier held by the Agency:

Part 1, Part 2, Part 3 and Part 4

1.4. Scientific advice

Not applicable

1.5. MUMS/limited market status

Not applicable.

2. Scientific Overview

The scope of this variation is to add a claim for associated mixed use between Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU to the product information of both products. Therefore, the product information of both products is affected by this variation. Since both executive summaries 2.G are affected, the MAH takes the opportunity to make some editorial changes to these documents.

In support of the claim for associated use between Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU, the MAH provided data on quality, safety and efficacy of the associated products.

The claim for associated use between Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU has been adequately supported by in-use stability data in accordance with EMA/CVMP/IWP/594618/2010. The absence of negative interactions after mixing of the individual IVMPs (e.g. virucidal effect and physio-chemical interactions) has been demonstrated using several associated vaccine lots.

The safety of the associated use of Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU was evaluated in one laboratory study under GLP conditions and in two field studies under GCP conditions. Taking into account the large number of animals that tolerated the vaccination well, it is possible to infer that vaccination with the associated mixed use of Ingelvac PRRSFLEX EU and Ingelvac CircoFLEX is safe in 17-day old piglets.

Efficacy

Overall, the studies performed by the MAH consistently support the claims for the reduction of lung lesions in PRRSV infected piglets and lymphoid lesions in PCV2 infected piglets. Results to support the claims for reduction of virus load (in PRRSV and PCV2 infected piglets), mortality (in PCV2 infected piglets) and negative effect of infection on ADWG (in PRRSV infected piglets), although limited, are considered sufficient in view of the complexity of the pathogenesis of the diseases.

The field studies, planned as non-inferiority studies, are supportive of the equivalence of the efficacy of the associated use compared to the use of the single products.

3. Benefit-risk assessment of the proposed change

Ingelvac CircoFLEX is authorised for immunisation of pigs from 2 weeks against porcine circovirus type 2 (PCV2) to reduce mortality, clinical signs - including weight loss - and lesions in lymphoid tissues associated with PCV2 related disease (PCVD). In addition, vaccination has been shown to reduce PCV2 nasal shedding, viral load in blood and lymphoid tissues and duration of viraemia.

Ingelvac PRRSFLEX EU is authorised for active immunisation of clinically healthy pigs from 17 days of age until the end of fattening and older from farms affected with European (genotype 1) porcine reproductive and respiratory syndrome virus (PRRSV) to reduce virus load in blood in seropositive animals. Under experimental challenge conditions in which only seronegative animals were included, it was demonstrated that vaccination reduces lung lesions, virus load in blood and lung tissues as well as negative effects of infection on daily weight gain. A significant reduction of the respiratory clinical signs could additionally be demonstrated at the onset of immunity.

The proposed variation is to add the associated mixed use of Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU. Additionally, the MAH is proposing some editorial changes to Part 2 of the Dossier and minor QRD updates to the product information.

3.1. Benefit assessment

Direct therapeutic benefit

The additional benefit of the associated use of Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU rely on the reduction of the number of vaccine administrations for pigs with positive effect on animal welfare.

3.2. Risk assessment

Quality:

Quality remains unaffected by this variation.

Safety:

Risks for the target animal:

Administration of Ingelvac CircoFLEX mixed with Ingelvac PRRSFLEX EU in accordance with SPC recommendations is generally well tolerated. Adverse reactions are limited to mild hypersensitivity-like reactions which may commonly occur after vaccination and resolve within few hours without treatment. Transient increase in body temperature and slight redness at the injection site may occur rarely.

Risk for the user:

The associated mixed use of Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU does not change the risk to the user when used in accordance with both SPCs.

Risk for the environment:

The associated mixed use of Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU is not expected to pose a risk for the environment when used according to the SPC recommendations. Standard advice on waste disposal is included in the SPC.

Risk for the consumer:

The associated non-mixed use of Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU is not expected to pose a risk to the consumer of foodstuffs derived from treated animals when both vaccines are used according to the proposed SPC recommendations.

3.3. Risk management or mitigation measures

Appropriate information has been included in the SPC and other product information to inform on the potential risks of this product relevant to the target animals.

3.4. Evaluation of the benefit-risk balance

Based on the data presented, the benefit-risk balance of the product following the changes proposed in this variation remains unchanged is deemed positive.

4. Conclusion

Based on the original presented on quality, safety and efficacy, the Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the application for variation to the terms of the marketing authorisation for Ingelvac CircoFlex can be approved since the data satisfy the requirements as set out in the legislation (Commission Regulation (EC) No. 1234/2008) and the benefit-risk balance remains positive.

Changes are required in the following Annexes to the Community marketing authorisation:

I, IIIA and IIIB

As a consequence of this variation, sections 2, 4.8, 4.9, 6.2, 6.5, 10 of the SPC are updated. The corresponding sections of the package leaflet are updated accordingly. Some editorial changes have been made to the labelling section.